Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations

Circulation

Volumn 94, Issue 11, 1996, Pages 2743-2748

  Robinson, Killian ^a   Gupta, Anjan ^a   Dennis, Vincent ^a   Arheart, Kristopher ^a   Chaudhary, Debashish ^a   Green, Ralph ^a   Vigo, Paul ^a   Mayer, Ellen L ^a   Selhub, Jacob ^b   Kutner, Michael ^a   Jacobsen, Donald W ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TUFTS UNIVERSITY   (United States)

Author keywords

coronary disease; kidney; risk factors

Indexed keywords

FOLIC ACID; PYRIDOXINE;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BRAIN ATHEROSCLEROSIS; CORONARY ARTERY ATHEROSCLEROSIS; FEMALE; HOMOCYSTINURIA; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL ANALYSIS;

EID: 10544252271     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.11.2743     Document Type: Article

References (45)

1. US Renal Data System, USRDS 1995 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; April 1995.
2. Rostand SG, Brunzell JD, Cannon RO, Victor RG. Cardiovascular complications in renal failure. J Am Soc Nephrol. 1991;2:1053-1062.
3. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med. 1974;290:697-701.
4. Ibels LS, Stewart JH, Mahony JF, Neale FC, Shell AGR. Occlusive arterial disease in uraemic and hemodialysis patients and renal transplant recipients. Q J Med. 1977;46:197-214.
5. Wilcken DEL, Gupta VJ. Sulphur-containing amino acids in chronic renal failure with particular reference to homocystine and cysteine-homocysteine mixed disulphide. Eur J Clin Invest. 1979;9:301-307.
6. Wilcken DEL, Gupta VJ, Reddy SG. Accumulation of sulphur-containing amino acids including cysteine-homocysteine in patients on maintenance hemodialysis. Clin Sci. 1980;58:427-430.
7. Wilcken DEL, Gupta VJ, Betts AK. Homocysteine in the plasma of renal transplant recipients: effects of cofactors for methionine metabolism. Clin Sci. 1981;61:743-749.
8. Bergstrom J, Alvestrand A, Furst P, Lindholm B. Sulphur amino acids in plasma and muscle in patients with chronic renal failure: evidence for taurine depletion. J Intern Med. 1989;226:189-194.
9. Chauveau P, Chadefaux B, Coudé M, Aupetit J, Hannedouche T, Kamoun P, Jungers P. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int. 1993;43(suppl 41):S72-S77.
10. Arnadottir M, Brattström L, Simonsen O, Thysell H, Hultberg B, Andersson A, Nilsson-Ehle P. The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin Nephrol. 1993;40:236-240.
11. Hultberg B, Andersson A, Sterner G. Plasma homocysteine in renal failure. Clin Nephrol. 1993;40:230-234.
12. Janssen MJFM, van den Berg M, Stehouwer CDA, Boers GHJ. Hyperhomocysteinaemia: a role in the accelerated atherogenesis of chronic renal failure? Neth J Med. 1995;46:244-251.
13. Bachmann J, Tepel M, Raidt H, Riezler R, Graefe U, Langer L, Zidek W. Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol. 1995;6:121-125.
14. Massy ZA, Chadefaux-Vekemans B, Chevalier A, Bader CA, Drueke TB, Legendre C, Lacour B, Kamoun P, Kreis H. Hyperhomocysteinaemia: a significant risk factor for cardiovascular disease in renal transplant recipients. Nephrol Dial Transplant. 1994;9:1103-1108.
15. Bostom AC, Shemin D, Lapane KL, Miller JW, Sutherland P, Nadeau M, Seyoum E, Hartman W, Prior R, Wilson PWF, Selhub J. Hyperhomocysteinemia and traditional risk factors in end-stage renal disease patients on dialysis: a case-control study. Atherosclerosis. 1995;114:93-103.
16. Laidlaw SA, Smolin LA, Davidson WD, Kopple JD. Sulfur amino acids in maintenance hemodialysis patients. Kidney Int. 1987;32 (suppl 22):S191-S196.
17. Hultberg B, Andersson A, Arnadottir M. Reduced free and total fractions of homocysteine and other thiol compounds in plasma from patients with renal failure. Nephron. 1995;70:62-67.
18. Wilcken DEL, Wilcken B. The pathogenesis of coronary artery disease: a possible role for methionine metabolism. J Clin Invest. 1976; 57:1079-1082.
19. Boers GHJ, Smals AGH, Trijbels FJM, Fowler B, Bakkeren JAJM, Schoonderwaldt HC, Kleijer WJ, Kloppenborg PWC. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med. 1985;313:709-715.
20. Brattström L, Israelsson B, Norrving B, Bergqvist D, Thörne J, Hultberg B, Hamfelt A. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease: effects of pyridoxine and folic acid treatment. Atherosclerosis. 1990;81:51-60.
21. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324:1149-1155.
22. Genest JJ Jr, McNamara JR, Salem DN, Wilson PWF, Schaefer EJ, Malinow MR. Plasma homocyst(e)ine levels in men with premature coronary artery disease. J Am Coll Cardiol. 1990;16:1114-1119.
23. Malinow MR, Rang SS, Taylor LM, Wong PWK, Coull B, Inahara T, Mukerjee D, Sexton G, Upson B. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation. 1989;79:1180-1188.
24. Taylor LM Jr, DeFrang RD, Harris J Jr, Porter JM. The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease. J Vasc Surg. 1991;13:128-136.
25. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 1992;268:877-881.
26. Graham IM. Homocysteinaemia and vascular disease. In: Vuylsteek K, Hallen M, eds. Commission of the European Community. Ios Press; 1994:332-353.
27. Robinson K, Mayer E, Miller D, Green R, van Lente F, Gupta A, Kottke-Marchant K, Savon S, Selhub J, Nissen SE, Kutner M, Topol EJ, Jacobsen DW. Hyperhomocysteinemia and low pyridoxal phosphate: common and independent reversible risk factors for coronary artery disease. Circulation. 1995;92:2825-2830.
28. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PWF, Belanger AJ, O'Leary DH, Wolf PA, Schaefer EJ, Rosenberg IH. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med. 1995;332:286-291.
29. Jacobsen DW, Gatautis VJ, Green R, Robinson K, Savon SR, Secic M, Ji J, Otto JM, Taylor LM Jr. Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalamin and folate levels in healthy subjects. Clin Chem. 1994;40:873-881.
30. Camp VM, Chipponi J, Faraj BA. Radioenzymatic assay for direct measurement of pyridoxal 5′-phosphate. Clin Chem. 1983;29:642-644.
31. Mudd SH, Levy HL, Skovby F. Disorders of transulfuration. In: Sen ver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of inherited Disease. 6th ed. New York, NY: McGraw Hill; 1989;693-734.
32. Mayer EM, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol. 1996;27:517-527.
33. Heinecke JW, Kawamura M, Suzuki L, Chait A. Oxidation of low density lipoprotein by thiols: superoxide-dependent and -independent mechanisms. J Lipid Res. 1993;34:2051-2061.
34. Parthasarathy S, Oxidation of low-density lipoprotein by thiol compounds leads to its recognition by the acetyl LDL receptor. Biochim Biophys Acta. 1987;917:337-340.
35. Glueck CJ, Shaw P, Lang J, Tracy T, Seive-Smith L, Wang Y. Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients. Am J Cardiol. 1995;75:132-136.
36. Black IW, Wilcken DEL. Decreases in apolipoprotein(a) after renal transplantation: implications for lipoprotein(a) metabolism. Clin Chem. 1992;38:353-357.
37. Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acad Sci U S A. 1992;89:10193-10197.
38. Ceballos I, Chauveau P, Guerin V, Bardet J, Parvy P, Kamoun P, Jungers P. Early alterations of plasma free amino acids in chronic renal failure. Clin Chim Acta. 1990;188:101-108.
39. Bostom AG, Brosnan JT, Hall B, Nadeau MR, Selhub J. Net uptake of plasma homocysteine by the rat kidney in vivo. Atherosclerosis. 1995;116:59-62.
40. Guttormsen AB, Svarstad E, Ueland PM, Refsum H. Elimination of homocysteine from plasma in subjects with end-stage renal failure. Ir J Med Sci. 1995;164(suppl 15):8-9.
41. Kopple JD, Mercurio K, Blumenkrantz MJ, Jones MR, Tallos J, Roberts C, Card B, Saltzman R, Casciato DA, Swendseid ME. Daily requirement for pyridoxine supplements in chronic renal failure. Kidney Int. 1981;19:694-704.
42. Wilcken DEL, Dudman NPB, Tyrrell PA, Robertson MR. Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: possible implications for prevention of vascular disease. Metabolism. 1988;37:697-701.
43. Guldener C, Janssen MJFM, van den Berg M, Stehouwer CDA, Donker AJM. Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients. Perit Dial Int. 1994;14(suppl 1):S26. Abstract2E
44. Janssen MJFM, Stehouwer CDA, van den Berg M, van der Meulen J, Boers GHJ, Donker AJM. Folic acid lowers elevated homocysteine concentrations in chronic dialysis patients. J Am Soc Nephrol. 1993; 4:250. Abstract.
45. Bostom AG, Shemin D, Lapane KL, Hume AL, Yoburn D, Nadeau M, Bendich A, Selhub J, Rosenberg IH. High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int. 1996; 49:147-152.